|
|||||
|
|
| 含表柔比星化疗方案作为乳腺癌术后辅助治疗的疗效观察 | |
| 引用本文： | 严鹏伟,黄新恩,姜勇,唐金海,许红霞,徐霞. 含表柔比星化疗方案作为乳腺癌术后辅助治疗的疗效观察[J]. 江苏医药, 2011, 37(8) |
| 作者姓名： | 严鹏伟 黄新恩 姜勇 唐金海 许红霞 徐霞 |
| 作者单位： | 1. 南京医科大学第一临床医学院,210029 2. 南京医科大学附属江苏省肿瘤医院化疗科 3. 南京医科大学附属江苏省肿瘤医院普通外科 |
| 基金项目： | 江苏省人事厅“六大人才高峰”项目(2005-6); 江苏省科技发展计划项目(BS2006006); 江苏省卫生厅“333高层次人才培养工程”项目(2005-19);江苏省卫生厅医学科技发展基金会康莱特基金(P200908) |
| 摘 要： | 目的探讨含表柔比星化疗方案作为乳腺癌术后辅助治疗的疗效。方法对555例接受含表柔比星方案辅助化疗的乳腺癌患者的总生存率(OS)及不良反应进行分析。结果 380例接受5-氟脲嘧碇/表柔比星/环磷酰胺(FEC组)方案、56例接受长春瑞滨/表柔比星(NE组)方案、82例接受紫杉醇/表柔比星(TE组)方案、37例接受紫杉醇/表柔比星/环磷酰胺(TEC组)方案,四种方案的5年生存率分别为83.6%、89.3%、86.7%和91.7%。Ⅲ度以上骨髓抑制、消化道反应及心脏事件发生率:FEC方案组分别为37.0%、24.9%、0.2%,NE方案组分别为34.6%、19.6%、0%,TE方案组分别为38.8%,17.0%,1.2%,TEC方案组分别为37.8%,18.9%,2.7%。结论含表柔比星的四种辅助治疗方案均能延长生存期,毒副作用可耐受。 |
| 关 键 词： | 表柔比星 乳腺癌 辅助化疗 |
Efficacy of epirubicine-containing regime as postoperative adjuvant chemotherapy for breast cancer |
|
| YAN Pengwei,HUANG Xinen,JIANG Yong,et al.. Efficacy of epirubicine-containing regime as postoperative adjuvant chemotherapy for breast cancer[J]. Jiangsu Medical Journal, 2011, 37(8) | |
| Authors: | YAN Pengwei HUANG Xinen JIANG Yong et al. |
| Affiliation: | YAN Pengwei,HUANG Xinen,JIANG Yong,et al.First Clinical Medical College,Nanjing Medical University,Nanjing 210029,CHINA |
| Abstract: | Objective To evaluate the efficacy of epirubicine-containing regime as postoperative adjuvant chemotherapy for breast cancer.Methods The overall survival(OS) and adverse effects of four adjuvant chemotherapeutic epirubicine-containing regimes were analyzed in 555 patients with breast cancer.Results The regime of 5-fluorouracil/epirubicine/cyclophosphamide(FEC) was used in 380 patients,vinorelbine/epirubicine(NE) regime in 56 cases,paclitaxel/epirubicine(TE) regime in 82 cases and paclitaxel/epirubicine/cycl... |
| Keywords: | Epirubicine Breast cancer Adjuvant chemotherapy |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |